Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...

The GLISTEN trial involved 238 PBC patients with moderate to severe itch across 19 countries. The drug is not currently approved in any market. 3rd party Ad.

LONDON - The European Medicines Agency has accepted GSK’s (LSE/NYSE:LON:GSK) marketing authorization application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

GSK plc announced that the European Medicines Agency has accepted for review the marketing authorisation application (MAA) for the use of linerixibat, an investigational targeted inhibitor of the ...

Health and wellness brand Life Time is set to open up its New York City flagship near Bryant Park, Commercial Observer has learned. Life Time, which operates around 185 health clubs across the U.S.

Pakistan Business Council Dubai: Successful AGM highlights milestones, community contributions, and strategic future plans besides fostering UAE-Pakistan economic collaboration.

Jock itch is typically easy to treat, but some cases can grow out of control or become resistant to treatment. Here’s what you need to know.